British Columbia Starts Biosimilar Switching Program
The Canadian province of British Columbia has announced a biosimilar switching program for etanercept, infliximab and insulin glargine that will see patients using original biologics switched to biosimilars within six months.
You may also be interested in...
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.